TrialDiabetes, obesity & metabolism2022

Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period.

Caroline Reilhac et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.